FY2026 Earnings Forecast for BMY Issued By Cantor Fitzgerald

Bristol-Myers Squibb (NYSE:BMY) – Equities researchers at Cantor Fitzgerald issued their FY2026 earnings per share estimates for shares of Bristol-Myers Squibb in a research report issued on Monday, June 9th. Cantor Fitzgerald analyst C. Gould expects that the biopharmaceutical company will post earnings per share of $6.04 for the year. Cantor Fitzgerald currently has a “Neutral” rating and a $55.00 target price on the stock. The consensus estimate for Bristol-Myers Squibb’s current full-year earnings is $6.74 per share.

BMY has been the subject of a number of other research reports. William Blair restated a “market perform” rating on shares of Bristol-Myers Squibb in a research report on Friday, April 25th. UBS Group reduced their price objective on Bristol-Myers Squibb from $60.00 to $54.00 and set a “neutral” rating for the company in a research report on Friday, April 11th. Piper Sandler assumed coverage on Bristol-Myers Squibb in a research report on Tuesday, April 22nd. They set an “overweight” rating and a $65.00 price objective for the company. Argus upgraded Bristol-Myers Squibb to a “hold” rating in a research report on Friday, April 25th. Finally, Wall Street Zen lowered Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research report on Friday, June 6th. Two research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $58.00.

Bristol-Myers Squibb Price Performance

Shares of BMY opened at $50.13 on Tuesday. The firm has a market cap of $102.01 billion, a price-to-earnings ratio of -11.34, a PEG ratio of 2.07 and a beta of 0.38. The stock has a 50 day moving average of $48.87 and a 200-day moving average of $54.88. The company has a current ratio of 1.25, a quick ratio of 1.15 and a debt-to-equity ratio of 2.90. Bristol-Myers Squibb has a 52 week low of $39.35 and a 52 week high of $63.33.

Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, topping the consensus estimate of $1.50 by $0.30. The company had revenue of $11.20 billion during the quarter, compared to analyst estimates of $10.77 billion. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. The business’s revenue was down 5.6% on a year-over-year basis. During the same quarter last year, the firm earned ($4.40) EPS.

Institutional Investors Weigh In On Bristol-Myers Squibb

Institutional investors and hedge funds have recently modified their holdings of the stock. Truist Financial Corp raised its position in shares of Bristol-Myers Squibb by 3.9% during the fourth quarter. Truist Financial Corp now owns 1,597,150 shares of the biopharmaceutical company’s stock worth $90,335,000 after purchasing an additional 60,365 shares during the period. Quilter Plc raised its position in shares of Bristol-Myers Squibb by 56.6% during the fourth quarter. Quilter Plc now owns 107,818 shares of the biopharmaceutical company’s stock worth $6,098,000 after purchasing an additional 38,977 shares during the period. Advyzon Investment Management LLC acquired a new stake in shares of Bristol-Myers Squibb during the fourth quarter worth $458,000. Covenant Asset Management LLC acquired a new position in Bristol-Myers Squibb during the fourth quarter valued at $279,000. Finally, Polar Asset Management Partners Inc. acquired a new position in Bristol-Myers Squibb during the fourth quarter valued at $16,651,000. 76.41% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Bristol-Myers Squibb

In related news, EVP Samit Hirawat bought 4,250 shares of the business’s stock in a transaction dated Friday, April 25th. The shares were bought at an average cost of $47.58 per share, with a total value of $202,215.00. Following the completion of the transaction, the executive vice president now directly owns 83,513 shares of the company’s stock, valued at approximately $3,973,548.54. This trade represents a 5.36% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 0.09% of the company’s stock.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.